Alembic Wins Tentative FDA Nod for First Generic Larotrectinib Capsules
Decision brief
Answer first · skim in under a minute
Alembic Pharmaceuticals received tentative FDA approval for generic larotrectinib capsules in 25 mg and 100 mg strengths. The move marks a key catalyst for Vitrakvi competition, with final launch timing still dependent on remaining patent or exclusivity issues.
Generic Larotrectinib Capsules Gain Tentative FDA approval after Alembic Pharmaceuticals received a tentative ANDA nod for 25 mg and 100 mg strengths matching Bayer’s Vitrakvi. Launch must wait for patent or exclusivity clearance. Sole first-filer Paragraph IV status may support 180 days of exclusivity after final approval.
Contents9 sections
Key Takeaways
- Alembic received tentative FDA approval for larotrectinib capsules 25 mg and 100 mg versus Vitrakvi.
- Tentative status means scientific approvability without immediate commercial launch rights.
- Alembic claims sole first-filer Paragraph IV status and potential 180-day exclusivity after final approval.
- Larotrectinib treats NTRK gene fusion–positive solid tumors meeting labeled criteria in adults and children.
What changed for Generic Larotrectinib Capsules Gain Tentative status?
On June 11, 2026, Alembic disclosed USFDA tentative approval of its ANDA for larotrectinib capsules 25 mg and 100 mg. The company said the ANDA is therapeutically equivalent to Bayer Healthcare Pharmaceuticals’ Vitrakvi capsules. Stock-exchange disclosure text is mirrored in public filings; product labeling for the brand reference remains on DailyMed Vitrakvi pages when checking the RLD indication.
What is larotrectinib used to treat?
Larotrectinib is a TRK kinase inhibitor for adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or unresectable without severe morbidity, and have no satisfactory alternatives or have progressed after treatment. Clinical development of the brand product included basket studies such as NCT02576431.
How does tentative approval differ from final approval?
FDA’s Orange Book framework separates products that are scientifically approvable from those that may be marketed. Tentative approval typically waits on patents, exclusivity, or pediatric exclusivity associated with the RLD. Teams should not treat tentative approval as a launch date. Orange Book files are available from FDA Orange Book data files.
Why Paragraph IV timing matters
Alembic said it is the sole first applicant with a Paragraph IV certification for these capsule strengths. If that status holds through final approval, Hatch-Waxman can confer 180 days of generic exclusivity. Competitive intelligence should verify Paragraph IV listings against FDA’s public PIV database updates rather than relying only on company claims.
Peer-reviewed context on larotrectinib’s tumor-agnostic role is summarized in literature such as PMC7863124.
What remains unproven
Final approval timing, litigation outcomes, and whether 180-day exclusivity is ultimately awarded remain open. Company filings cite roughly $91 million in U.S. brand capsule sales for a recent 12-month IQVIA window; treat that as market context, not an FDA finding. Alembic also reported a cumulative 241 USFDA ANDA approvals (221 final and 20 tentative) at the time of the June 11, 2026 disclosure. Access impact after launch will depend on payer contracts and residual brand contracting.
Related NovaPharma coverage
- Apotex Receives FDA Approval for First Generic Infuvite Adult Injection with 180-Day Exclusivity
- Lupin Launches Generic Dapagliflozin-Metformin XR Tablets in US
- FDA guidance on sharing potential NDA patent information
Frequently Asked Questions
What does it mean that Generic Larotrectinib Capsules Gain Tentative FDA approval?
Tentative approval means FDA has determined the ANDA meets scientific and quality standards for approval, but final approval and marketing must wait until remaining patent or exclusivity barriers for the reference listed drug are resolved.
What strengths did Alembic receive for generic larotrectinib capsules?
Alembic Pharmaceuticals announced tentative FDA approval for larotrectinib capsules in 25 mg and 100 mg strengths, therapeutically equivalent to Bayer’s Vitrakvi capsules in the same strengths.
Could Alembic get 180-day exclusivity for generic larotrectinib?
Alembic stated it is the sole first applicant to file an ANDA for larotrectinib capsules with a Paragraph IV certification. Upon final FDA approval, the company may be eligible for 180 days of generic marketing exclusivity under Hatch-Waxman.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for larotrectinib.
Unlock full calendar →pharmaand GmbH pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
